AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
In 1929–30, Parke, Davis & Co., a major US drug manufacturer based in Detroit, Michigan, sold "Opium, U.S.P. (Laudanum)", as Tincture No. 23, for $10.80 per pint (16 fluid ounces), and "Opium Camphorated, U.S.P. (Paregoric)", as Tincture No. 20, for $2.20 per pint. Concentrated versions were available. "Opium Camphorated, for U.S.P. Tincture: Liquid No. 338" was "exactly 8 times the strength of Tincture Opium Camphorated (Paregoric) [italics in original], U.S.P., "designed for preparing the tincture by direct dilution," and cost $7 per pint. Similarly, at a cost of $36 per pint, "Opium Concentrated, for U.S.P. Tincture: Liquid No. 336", was "four times the strength of the official tincture", and "designed for the extemporaneous preparation of the tincture". The catalog also noted: "For quarter-pint bottles add 80c. per pint to the price given for pints." Toward the middle 20th century, the use of opiates was generally limited to the treatment of pain, and opium was no longer a medically accepted 'cure-all'. Further, the pharmaceutical industry began synthesizing various opioids, such as propoxyphene, oxymorphone and oxycodone. These synthetic opioids, along with codeine and morphine were preferable to laudanum since a single opioid could be prescribed for different types of pain rather than the 'cocktail of laudanum, which contains nearly all of the opium alkaloids. Consequently, laudanum became mostly obsolete as an analgesic, since its principal ingredient is morphine, which can be prescribed by itself to treat pain.
Banlieue Triste was already attracting attention, wrote Frank Colombani of Le Monde, and the band were therefore courted by the Spinefarm Records label. Spinefarm Records released the album on 28 September 2018 in all territories outside France. A special double-vinyl edition of the album was released simultaneously, following the signing of the quartet Chanut, Thépegnier, Hanvic, and Toufouti to Spinefarm Records, thereby guaranteeing worldwide distribution for their future recordings. Hope /// Dope /// Rope, This Is Not Supposed To Be Positive and Banlieue Triste "are part of a whole", thus constituting a "trilogy", Chanut said. Banlieue Triste led the band to appear on the French television channel Canal+ for a short concert on the programme L'album de la Semaine (lit. 'Album of the Week'), to be broadcast on FIP and France Inter, and to be featured in articles in the general-interest press. While the band frequently toured the Upper France region during the winter of 2018, they opened for Zeal & Ardor at L'Aéronef in Lille and for Samael in Dunkirk. They regularly performed in Belgium and the Netherlands because their manager was based in Lille. The single "Lost Brothel" was released in July 2019, ahead of a four-track EP titled Bus de Nuit (lit. 'Night Bus'). On 16 August 2019, Hangman's Chair performed at the Psycho Las Vegas festival in Nevada, US. A joint performance by Hangman's Chair and the post-black metal band Regarde Les Hommes Tomber (lit.
=== Software code === In January 2020, Check Point Research discovered a vulnerability through which a hacker could spoof TikTok's official SMS messages and replace them with malicious links to gain access to user accounts. It was later patched by TikTok. In August 2020, The Wall Street Journal reported that TikTok tracked Android user data, including MAC addresses and IMEIs, with a tactic in violation of Google's policies. In August 2022, software engineer and security researcher Felix Krause found that in-app browsers from TikTok and other platforms contained codes for keylogger functionality but did not have the means to further investigate whether any data was tracked or recorded. TikTok said that the code is disabled.
Sources: en.wikipedia.org
ISBN 978-1-119-54212-4. OCLC 1083261548. Stvrtinová V, Jakubovský J, Hulín I (1995). Pathophysiology: Principles of Disease. Computing Centre, Slovak Academy of Sciences: Academic Electronic Press. Swartz, Mark H. (2010). Textbook of Physical Diagnosis: History and Examination (6th ed.). Saunders/Elsevier. ISBN 978-1-4160-6203-5. Concise Oxford Companion to the English Language 1998 entries on classical compound and combining form Taber, Clarence Wilbur; Thomas, Clayton L.; Venes, Donald (2001). Taber's cyclopedic medical dictionary (Ed. 19, illustrated in full color ed.). Philadelphia: F.A.Davis Co. ISBN 0-8036-0655-9. ISSN 1065-1357. Waquet, Françoise (2001). Latin, or the Empire of a Sign: From the Sixteenth to the Twentieth Centuries. Translated by John Howe. Verso. ISBN 1859844022.
The ancient Indian sexual treatise Kama Sutra, written in Sanskrit, probably between the second and fourth centuries AD, divides men into three classes based on penis size: "hare" size (about 5–7 cm, or 2–3 inches, when erect), "bull" size (10–15 cm, or 4–6 inches), and "horse" size (18–20 cm, or 7–8 inches). The treatise also divides women's vaginas into three sizes ("deer", "mare", and "elephant") and advises that a man match the size of the vagina of the woman he is having sex with to the size of his own penis. It also gives medically dubious advice on how to enlarge one's penis using wasp stings.
Hunter requested greater control by authorities in England and an excise duty on rum. He issued an order restricting the amount of convict labour that officers could use, but again had no means to enforce it. Hunter was strongly opposed by officers of the Corps, and pamphlets and letters against him were circulated. John Macarthur wrote a letter accusing Hunter of ineffectiveness and trading in rum. Hunter was required by the Colonial Office to answer the charges, and soon after was recalled for being ineffective. In 1799 Paterson, now a Lieutenant Colonel, returned from England with orders to stamp out the trading in rum by officers of the Corps. In 1800, he charged Major George Johnston, who had served as Hunter's aide-de-camp, with giving a sergeant part payment in rum at an exorbitant rate. Johnston claimed he was being unfairly persecuted and demanded that he be sent to England for trial. The English courts decided that colonial affairs were not a matter for them and, as all the evidence and witnesses were in Sydney, that any trial should be held there. They decided that, as proper court martial could not be constituted in Sydney, no further action should be taken against Johnston. Governor Philip King, appointed in September 1800, continued Hunter's efforts to prevent the Corps trading in rum. He had the power to levy an excise duty on alcohol, and the Transit Board now required all ships to lodge a bond which was forfeit for disobeying the Governor's orders, which included the prohibition of the landing of more than 500 gallons of rum.
=== Choline acetyltransferase deficiencies === Choline acetyltransferase (also known as ChAT or CAT) is an important enzyme which produces the neurotransmitter acetylcholine. Acetylcholine is involved in many neuropsychic functions such as memory, attention, sleep and arousal. The enzyme is globular in shape and consists of a single amino acid chain. ChAT functions to transfer an acetyl group from acetyl co-enzyme A to choline in the synapses of nerve cells and exists in two forms: soluble and membrane bound. The ChAT gene is located on chromosome 10.
Sources: en.wikipedia.org
==== Custom manufacturing ==== The products and services offered by the fine chemical industry fall into two broad categories: (1) "Exclusives" or custom manufacturing (CM) and (2) "standard" or "catalogue" products. "Exclusives", provided mostly under contract research or custom manufacturing arrangements, prevail in business with life science companies; "standards" prevail in other target markets. Service-intense custom manufacturing constitutes the most prominent activity of the fine chemical industry. Custom manufacturing is the antonym of outsourcing. In custom manufacturing, a specialty-chemicals company outsources the process development, pilot plant, and industrial-scale production of an active ingredient, or a predecessor thereof, to one, or a few, fine chemical companies. The intellectual property of the product, and generally also the manufacturing process, stay with the customer. The customer-supplier relationship is governed by an exclusive supply agreement. At the beginning of cooperation, the customer provides a "tech package" which, in its simplest version, includes a laboratory synthesis description and SHE recommendations. In this case, the whole scale up, which comprises a factor of about one million (10 gram → 10 ton quantities), is done by the fine chemical company.
== Contraindications == Contraindications are severe respiratory or liver impairment and acute alcoholism. There are limited accounts of cross-reactivity with opioids, but there is a possibility. Serious central nervous system (CNS) and respiratory depression may also occur with concurrent use of CNS depressants, ingesting alcohol, or other CNS-depressing factors while on buprenorphine/naloxone.
This was Merck's first use of the designation and the reduction in regulatory risk was one of the reasons management was willing to put company resources into development. In 2013, the United States Adopted Name (USAN) name was changed from lambrolizumab to pembrolizumab. In that year clinical trial results in advanced melanoma were published in The New England Journal of Medicine. This was part of the large phase I NCT01295827 trial. In September 2014, the US Food and Drug Administration (FDA) approved pembrolizumab under the Fast Track Development Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation. As of 2015, the only PD-1/PD-L1 targeting drugs on the market are pembrolizumab and nivolumab. By April 2016, Merck applied for approval to market the drug in Japan and signed an agreement with Taiho Pharmaceutical to co-promote it there. In July 2015, pembrolizumab received marketing approval in the European Union. In October 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) in people whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents. In July 2016, the US FDA accepted for priority review an application for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after a platinum-based chemotherapy.
BioShock is a first-person shooter with role-playing customization and stealth elements, and is similar to System Shock 2. The player takes the role of silent protagonist Jack as he is guided through Rapture towards various objectives. The player battles enemies using a combination of traditional weaponry and magic-like plasmids. Aside from the wrench, a melee weapon, players can upgrade their weapons through upgrade stations scattered across the environment; these upgrades modify weapons with added range, lessened recoil, or similar improvements. Weapons can also be equipped with different ammo types to increase effectiveness against varied targets. Plasmids confer superpowers such as casting fire or electric attacks, and in some cases can be used to access new areas—for example, melting ice blocking a path, or tripping the electric lock to open a door. Using plasmids requires EVE—the equivalent of mana—which can be replenished with EVE hypos or certain consumable food and drink. The player has a health meter that decreases when they take damage. The player can restore their health with food or medical packs found throughout Rapture. If the player's health is reduced to zero, they will respawn at a nearby Vita-Chamber, a device that functions as a checkpoint system. A patch for the game allows the Vita-Chambers to be turned off, requiring players to restart a saved game if the character dies.
The Morgan State University Choir has performed for audiences throughout the United States and internationally. Robert Shaw has directed them, together with the Orchestra of St. Lukes and Jessye Norman and others in Carnegie Hall's One Hundredth Birthday Tribute to Marian Anderson. In the 1996-1997 season, the "Silver Anniversary" concert was broadcast throughout the state of Maryland. The concert won an Emmy Award for Maryland Public Television. During 2011-2012 academic years, the choir had several prominent performances. Since 2017, the Morgan State University choir has toured Cuba, Spain, Portugal, Austria, Slovakia, Germany, England, Scotland, Wales, Peru, Ecuador, and the Galapagos Islands. In December 2021, the choir sang a concert in Hawaii, to commemorate the eightieth anniversary of the bombing of Pearl Harbor.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.